How to buy RedHill Biopharma stock - 07 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy RedHill Biopharma stock

Own RedHill Biopharma stock in just a few minutes.

Fact checked

RedHill Biopharma Ltd is a drug manufacturers-specialty & generic business based in the US. RedHill Biopharma shares (RDHL) are listed on the NASDAQ and all prices are listed in US Dollars. RedHill Biopharma employs 155 staff and has a trailing 12-month revenue of around USD$44.5 million.

How to buy shares in RedHill Biopharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for RedHill Biopharma. Find the stock by name or ticker symbol: RDHL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until RedHill Biopharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of RedHill Biopharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of RedHill Biopharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

RedHill Biopharma share price

Use our graph to track the performance of RDHL stocks over time.

RedHill Biopharma shares at a glance

Information last updated 2021-03-02.
52-week rangeUSD$3.2621 - USD$11.52
50-day moving average USD$8.9201
200-day moving average USD$8.9567
Wall St. target priceUSD$22
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.47

Buy RedHill Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy RedHill Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

RedHill Biopharma financials

Revenue TTM USD$44.5 million
Gross profit TTM USD$4 million
Return on assets TTM -32.82%
Return on equity TTM -246.27%
Profit margin -142.81%
Book value $0.771
Market capitalisation USD$324.4 million

TTM: trailing 12 months

Shorting RedHill Biopharma shares

There are currently 2.4 million RedHill Biopharma shares held short by investors – that's known as RedHill Biopharma's "short interest". This figure is 5.9% down from 2.6 million last month.

There are a few different ways that this level of interest in shorting RedHill Biopharma shares can be evaluated.

RedHill Biopharma's "short interest ratio" (SIR)

RedHill Biopharma's "short interest ratio" (SIR) is the quantity of RedHill Biopharma shares currently shorted divided by the average quantity of RedHill Biopharma shares traded daily (recently around 759826.81388013). RedHill Biopharma's SIR currently stands at 3.17. In other words for every 100,000 RedHill Biopharma shares traded daily on the market, roughly 3170 shares are currently held short.

However RedHill Biopharma's short interest can also be evaluated against the total number of RedHill Biopharma shares, or, against the total number of tradable RedHill Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case RedHill Biopharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 RedHill Biopharma shares in existence, roughly 60 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable RedHill Biopharma shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against RedHill Biopharma.

Find out more about how you can short RedHill Biopharma stock.

RedHill Biopharma share dividends

We're not expecting RedHill Biopharma to pay a dividend over the next 12 months.

RedHill Biopharma share price volatility

Over the last 12 months, RedHill Biopharma's shares have ranged in value from as little as $3.2621 up to $11.52. A popular way to gauge a stock's volatility is its "beta".

RDHL.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while RedHill Biopharma's is 1.6217. This would suggest that RedHill Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

RedHill Biopharma overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site